Theratechnologies to Present at the Cantor Oncology, Hematology & HemeOnc Conference
MONTREAL, Sept. 19, 2022 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Levesque, President and Chief Executive Officer, will participate on the “Novel Targets in Oncology: Risk vs. Reward” panel, at the Cantor Oncology, Hematology & HemeOnc Conference to be held at the New York Palace Hotel, on Wednesday, September 28, 2022, at 9:00 a.m. ET, in New York City. The presentation is available only to attendees of the conference: https://www.cantor.com/cantor-oncology-hemonc-conference/
Related news for (THTX)
- Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIV
- Theratechnologies Provides Update on Sale Process
- Breaking News: MoBot’s Latest Update as of 04/14/25 09:00 AM
- MoBot alert highlights: NASDAQ: XHG, NASDAQ: STSS, NASDAQ: DMN, NASDAQ: THTX, NASDAQ: KIDZ (04/14/25 05:00 AM)
- Breaking News: MoBot’s Latest Update as of 04/14/25 04:00 AM